期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

盐酸替罗非班对急性冠脉综合征梗死相关血管TIMI血流的影响 被引量：1

Effect of Tirofiban on TIMI flow in patients with acute coronary syndrome
下载PDF
导出
摘要 目的分析GPⅡb/Ⅲa受体拮抗剂盐酸替罗非班对急性冠脉综合征(ACS)患者心肌梗死溶栓试验(TIMI)血流的影响。方法选择急诊入院的ACS患者57例,分为试药组(盐酸替罗非班)29例和对照组28例。收集所有病例的临床和冠状动脉造影资料,观察两组TIMI血流情况。结果试药组梗死相关血管TIMI血流分级显著提高,试药组达Ⅰ级以上血流者比例显著高于对照组(97%vs64%,P<0.01);对照组完全闭塞者比例显著高于试药组(36%vs3%,P<0.01)。结论盐酸替罗非班可以改善ACS患者梗死相关血管TIMI血流。 AIM To evaluate the effect of Tirofiban on TIMI flow in patients with acute coronary syndrome （ACS）. METHODS Fifty-seven patients with ACS who would have selective coronary angiography （SCA） were randomly divided into two groups： Tirofiban ＋ SCA group （n = 29） and the SCA group （ n = 28）, and TIMI flow was examined angiographically. RESULTS A greater percentage of TIMI ≥1 flow was achieved in Triofiban ＋ SCA group compared with that in SCA group （97% vs 64%, P 〈 0.05 ）. The percentage of TIMI 0 flow was significantly higher in SCA group compared with that in Tirofiban ＋ SCA group （36% vs 3%, P 〈 0.01 ）. CONCLUSION Tirofiban improves TIMI flow of IRA in patients with ACS.
作者 夏豪 谭安安 周桃 胡波
机构地区 武汉大学人民医院心内科
出处 《心脏杂志》 CAS 2008年第1期49-50,57,共3页 Chinese Heart Journal
基金 国家留学回国人员科技活动项目资助
关键词 盐酸替罗非班 冠脉综合征 急性 冠状动脉血管造影 选择性 tirofiban acute coronary syndrome selective coronary angiography
分类号 R541.4 [医药卫生—心血管疾病]
  • 相关文献

参考文献10

  • 1Lefkovits J, Plow EF, Topoi EJ. Platelet glycopmtein Ⅱb/Ⅲ a receptor in cardio-vascular medicine[ J ]. N Engl J Med, 1995,332( 23 ) : 1553 - 1558.
  • 2I Montalescot G, Barragan P, Wittenbery O, et al. Platelet glycoprotein Ⅱ b/Ⅲ a inhibition with coronary stenting for acute myocardial infarction [ J ]. N Eng J Med,2001,344 (25) :1895 -1903.
  • 3Lee DP, Hefity NA, Hiatt BL,et al. Adjunctive platelet glycopmtein Ⅱ b/Ⅲ a inhibition with timfiban before primary angioplasty improves angiographic outcome:Results of the timfiban give in the Emergency room before primary angioplasty (TIGER-PA)pilot trial [J]. Circulation,2003,107( 11 ) :1497 - 1501.
  • 4Rasoul S,Ottervanger JP, de Boer MJ,et al. A comparison of dual vs. triple antiplatelet therapy in patients with non-ST-segment elevation acute coronary syndrome : results of the ELISA-2 trial [ J ]. Eur Heart J,2006 ,27(12) :1401 - 1407.
  • 5陈灏珠,主编.实用内科学[M] 第12版.北京:人民卫生出版社,2005.1 579-1 582.
  • 6The TIMI Study Group. The thrombolysis in myocardial infarction (TIMI) trial, phase I findings. TIMI Study Group [ J ]. N Engl Med, 1985,312(14) :932 -936.
  • 7邹阳春.急性冠脉综合征(3)[J].中国医药导刊,2005,7(3):222-228. 被引量：6
  • 8Elmouchi DA, Bates ER. Platelet glycoprotein Ⅱ b/Ⅲ a inhibitor therapy in non-ST segment elevation acute coronary syndromes [ J ]. Minerva Cardioangiol,2003,51 ( 5 ) :547 - 560.
  • 9Shen YT, Wiedmann RT, Lynch JJ Jr,et al. Platelet glycol-protein Ⅱ b/Ⅲ a receptor inhibitor preserves coronary flow reserve during progressive coronary arteriostenosis in swine [ J ]. Arterioscler Thromb Vasc Biol,2000 ,20(10 ) :2309 -2315.
  • 10徐邦牢,贝春花,黎镇赐,雷秀霞,王蓉.急性冠状动脉综合征早期盐酸替罗非班治疗对血清可溶性CD40配体水平的影响[J].中国心血管杂志,2006,11(2):99-100. 被引量：11

二级参考文献7

  • 1顾晴,陈纪林,阮英茆.阿司匹林、氯吡格雷及合用对兔动脉粥样硬化病变进展的抑制作用[J].中国医学科学院学报,2005,27(1):87-91. 被引量：46
  • 2Henn V, Slupsky JR,Grafe M,et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells[J]. Nature, 1998, 391 : 591-594.
  • 3Graf D, Mullar S, Korthauer U, et al. A soluble form of TRAP(CD40 ligand) is rapidly released after T cell activation[J].Eur J Immunol, 1995, 25: 1749-1754.
  • 4Andre P, Nannizzi-Alaimo L, Prasad SK, et al. Platelet-derived CD40L: the switch-hitting player of cardiovascular disease[J]. Circulation, 2002, 106:896-899.
  • 5Wagner AH, Gebauer M. 3-hydroxy-3-methylglutaryl coenzyme A reductase-independent inhibition of CD40 expression by atorvastatin in human endothelial cells[J]. Arterioscler Thromb Vasc Biol,2002,11: 1784- 1789.
  • 6Cyrus T,Sung S,Zhao L,et al. Effect of low-dose aspirin on vascular inflammation, plaque stability, and antherogenesis in low-density lipoprotein receptor-deficient mice[J]. Circulation, 2002,106 : 1282-1287.
  • 7唐熠达,陈纪林,阮英茆,徐新林,王清峙,司文学,张连庄,杨跃进,高润霖,陈在嘉.不同剂量阿司匹林对兔动脉粥样硬化斑块进展的抑制作用[J].中华心血管病杂志,2003,31(8):609-612. 被引量：41

共引文献368

同被引文献16

  • 1方唯一.冠脉复杂病变介入治疗[J].中国心血管病研究,2005,3(7):483-485. 被引量：10
  • 2张燕,刘鹏,李靖.替罗非班对冠心病PCI术中内皮功能障碍影响的研究[J].中国误诊学杂志,2006,6(16):3069-3071. 被引量：8
  • 3卢竞前,洪云飞,杨锋,李易,李建美,吕云,李玉,张荣华.国产替罗非班治疗急性冠脉综合征的临床观察[J].中国心血管病研究,2007,5(5):334-337. 被引量：4
  • 4Abbo KM,Dooris M,Glazier S,et al.Features and outcome of no-reflow after percutaneous coronary intervention.Am J Cardiol,1995,75:778-782.
  • 5Henriques JP,Zijlstra F,Ottervanger JP,et al.Incidence and clinical significance of distal embolization during primary angjoplasty for acute myocardial infarction.Eur Heart J,2002,23:1112-1117.
  • 6Valgimigli M,Campo G,Percoco G,et al.Comparison of angioplasty with infusion of tirofiban or abciximab and with im plantation of sirolimus -eluting or uncoated stents for acute myocardial infarction:the MULTISTRATEGY randomized trial.JAMA,2008,299:1788-1799.
  • 7Danzi GB,Capuano C,Sesana M,et al.Variability in extent of platelet function inhibition after administration of optimal dose of glycoprotein Ⅱb/Ⅲ a receptor blockers in patients undergoing a high risk percutaneous coronary intervention.Am J Cardiol,2006,97:489-493.
  • 8Huber K,Holmes DR Jr.van't Hof AW,et al.Use of glycoprotein Ⅱb/Ⅲa inhibitors in primary percutaneous coronary intervention:insights from the APEX-AMI trial.Eur Heart J,2010,31:1708-1716.
  • 9Montalescot G,Barragan P,Wittenberg O.et al.Platelet glycoprotein Ⅱb/Ⅲ a inhibition with coronary stenting for acute myocardial infarction.N Engl J Med,2001,344:1895-1903.
  • 10Heitzer T,Ollmann I,Koke K,et al.Platelet glycoprotein Ⅱb/Ⅲ a receptor blockade improves vascular nitric oxide bioavailability in patients with coronary artery disease.Circulation,2003,108:536-541.

引证文献1

二级引证文献3

心脏杂志
2008年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部